Custom Search


Saturday 01 April 2006

Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab.

By: Chaudhary N, Ozer H, Huard D, Lightfoot S, Mesiya S.

Dig Dis Sci 2006 Apr;51(4):775-8

Helicobacter pylori infection is strongly associated with low-grade gastric lymphoma, commonly known as mucosa-associated lymphoid tissue (MALT) lymphoma. H. pylori eradication leads to complete remission in 80% of early stage MALT lymphomas. The treatment for early stage H. pylori-negative gastric MALT lymphoma is evolving. Rituximab, a chimeric anti-CD20 antibody, has shown response rates of approximately 50% with minimal toxicity in patients with B-cell non-Hodgkin lymphoma. We describe herein the clinical, endoscopic, and histologic features of a patient with H. pylori-negative gastric MALT lymphoma treated successfully with rituximab.

Use of this site is subject to the following terms of use